JP2005530735A - 癌の処置のための併用療法 - Google Patents

癌の処置のための併用療法 Download PDF

Info

Publication number
JP2005530735A
JP2005530735A JP2003585723A JP2003585723A JP2005530735A JP 2005530735 A JP2005530735 A JP 2005530735A JP 2003585723 A JP2003585723 A JP 2003585723A JP 2003585723 A JP2003585723 A JP 2003585723A JP 2005530735 A JP2005530735 A JP 2005530735A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
warm
effective amount
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003585723A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005530735A5 (enExample
Inventor
リャン，アンダーソン・ジョーゼフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0208680A external-priority patent/GB0208680D0/en
Priority claimed from GB0218388A external-priority patent/GB0218388D0/en
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2005530735A publication Critical patent/JP2005530735A/ja
Publication of JP2005530735A5 publication Critical patent/JP2005530735A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2003585723A 2002-04-16 2003-04-14 癌の処置のための併用療法 Pending JP2005530735A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0208680A GB0208680D0 (en) 2002-04-16 2002-04-16 Combination therapy
GB0218388A GB0218388D0 (en) 2002-08-08 2002-08-08 Combination therapy
PCT/GB2003/001617 WO2003088971A1 (en) 2002-04-16 2003-04-14 Combination therapy for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2005530735A true JP2005530735A (ja) 2005-10-13
JP2005530735A5 JP2005530735A5 (enExample) 2006-05-11

Family

ID=29252451

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003585723A Pending JP2005530735A (ja) 2002-04-16 2003-04-14 癌の処置のための併用療法

Country Status (16)

Country Link
US (1) US20050215530A1 (enExample)
EP (1) EP1496909B1 (enExample)
JP (1) JP2005530735A (enExample)
KR (1) KR20040103964A (enExample)
CN (1) CN100352441C (enExample)
AT (1) ATE353650T1 (enExample)
AU (1) AU2003216558B2 (enExample)
BR (1) BR0309226A (enExample)
CA (1) CA2482591A1 (enExample)
DE (1) DE60311788T2 (enExample)
ES (1) ES2280735T3 (enExample)
IL (1) IL164564A0 (enExample)
MX (1) MXPA04010166A (enExample)
NO (1) NO20044498L (enExample)
NZ (1) NZ535739A (enExample)
WO (1) WO2003088971A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
BRPI0411567A (pt) * 2003-06-18 2006-08-01 Angiogene Pharm Ltd uso de zd6126 ou um seu sal farmaceuticamente aceitável e um dentre 5-fu, cpt-11, e 5-fu e cpt-11, composição farmacêutica, kit, e, métodos para a produção de um efeito de dano vascular em um animal de sangue quente e para o tratamento de um cáncer envolvendo um tumor sólido em um animal de sangue quente
KR100872204B1 (ko) * 2003-10-15 2008-12-09 오에스아이 파마슈티컬스, 인코포레이티드 이미다조피라진 티로신 키나제 억제제
DE602005014964D1 (de) 2004-04-02 2009-07-30 Osi Pharm Inc Mit einem 6,6-bicyclischen ring substituierte heterobicyclische proteinkinaseinhibitoren
US20100063074A1 (en) * 2004-06-03 2010-03-11 Berger Mark S Cancer Treatment Method
CN1968706A (zh) 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
FR2886151B1 (fr) * 2005-05-31 2007-09-07 Mayoly Spindler Soc Par Action Utilisation de la colchicine pour la preparation d'un medicament destine a la prevention et/ou au traitement de l'endometriose
US8575164B2 (en) * 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP2011510018A (ja) * 2008-01-18 2011-03-31 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 癌治療のためのイミダゾピラジノール誘導体
EP2283020B8 (en) * 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
EP2408479A1 (en) 2009-03-18 2012-01-25 OSI Pharmaceuticals, LLC Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor
EP2421837A1 (en) 2009-04-20 2012-02-29 OSI Pharmaceuticals, LLC Preparation of c-pyrazine-methylamines
JP2012526138A (ja) * 2009-05-07 2012-10-25 オーエスアイ・ファーマシューティカルズ，エルエルシー 副腎皮質癌を治療するためのｏｓｉ−９０６の使用
WO2012129145A1 (en) 2011-03-18 2012-09-27 OSI Pharmaceuticals, LLC Nscle combination therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9714249D0 (en) * 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EE200200565A (et) * 2000-03-31 2004-06-15 Angiogene Pharmaceuticals Ltd. Vaskulaarse kahjustava toimega kombinatsioonravi
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy

Also Published As

Publication number Publication date
DE60311788T2 (de) 2007-11-22
EP1496909A1 (en) 2005-01-19
ES2280735T3 (es) 2007-09-16
MXPA04010166A (es) 2005-02-03
WO2003088971A1 (en) 2003-10-30
DE60311788D1 (de) 2007-03-29
CA2482591A1 (en) 2003-10-30
KR20040103964A (ko) 2004-12-09
AU2003216558A1 (en) 2003-11-03
AU2003216558B2 (en) 2008-05-29
EP1496909B1 (en) 2007-02-14
NZ535739A (en) 2008-01-31
CN100352441C (zh) 2007-12-05
BR0309226A (pt) 2005-02-09
HK1071310A1 (en) 2005-07-15
IL164564A0 (en) 2005-12-18
CN1658880A (zh) 2005-08-24
US20050215530A1 (en) 2005-09-29
ATE353650T1 (de) 2007-03-15
NO20044498L (no) 2004-11-04

Similar Documents

Publication Publication Date Title
US20100130493A1 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
JP2005530735A (ja) 癌の処置のための併用療法
US20100179142A1 (en) Cancer Combination Therapy Comprising AZD2171 and ZD1839
EP1651227B1 (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
KR20080031029A (ko) Ａｚｄ2171 및 젬시타빈에 의한 암의 병용 요법
HK1071310B (en) Combination therapy for the treatment of cancer
AU2003252976B2 (en) Combination of VEGF receptor tyrosine kinase inhibitors for treatment of cancer
HK1089384B (en) Pharmaceutical compositions comprising azd 2171 and zd 6126 and uses thereof
HK1089667B (en) Cancer combination therapy comprising azd2171 and zd1839

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090728

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091222